retatrutide triple agonist glp-1 gip glucagon phase 2 obesity A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Retatrutide, a TRIPLE agonist (GLP1,

In some cases, these lower-cost medications may be administered with a vial and syringe, or in pill form, rather than via easy-to-use prefilled injector pens

This neurological approach helps curb cravings and overeating, making it easier to adhere to a healthy diet and achieve weight loss goals

The first genetic biomarkers of GLP-1 efficacy PrecisionLife and Ovation identified the first genetic biomarkers to quantitatively predict GLP-1 efficacy response

While most eye changes associated with GLP-1 therapy are manageable or temporary, serious complications like advanced diabetic retinopathy can potentially cause lasting vision impairment if not addressed promptly

Referred to as comorbidities, these concerns range from high blood pressure, diabetes, sleep apnea, arthritis, stress incontinence, acid reflux, hypercholesterolemia (high cholesterol), and beyond